Immunomedics, Inc. IMMU was a big mover last session, as the company saw its shares rise nearly 5% on the day. This stock, which remained volatile and traded within the range of $9.48 – $17.16 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen one negative estimate revision in the past two months, while its Zacks Consensus Estimate for the current quarter has also moved lower in the same time frame, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Immunomedics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Immunomedics, Inc. Price
A better-ranked stock in the Medical – Biomedical and Genetics industry is Acorda Therapeutics, Inc. ACOR, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report
Immunomedics, Inc. (IMMU): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.